Theravance Biopharma (NASDAQ:TBPH) Reaches New 1-Year High - Here's What Happened

Key Points

• Theravance Biopharma shares reached a new 12-month high of $14.40, marking a significant increase from a previous close of $13.88.
• Analysts have upgraded the stock, with a consensus rating of "Strong Buy" and a price target of $21.33, following upgrades from several research firms.
• Insiders and institutional investors are actively trading shares, indicating confidence in the company, with insider ownership at 6.9% and institutional ownership at 99.1%.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) hit a new 52-week high on Tuesday . The stock traded as high as $14.37 and last traded at $14.40, with a volume of 270840 shares traded. The stock had previously closed at $13.88.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Zacks Research raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Friday, August 15th. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Jones Trading raised shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price on the stock in a research report on Tuesday, June 17th. Finally, BTIG Research boosted their target price on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, June 27th. Two investment analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. Based on data from MarketBeat, Theravance Biopharma currently has an average rating of "Strong Buy" and a consensus target price of $21.33.

Theravance Biopharma Stock Performance

The company has a market capitalization of $702.52 million, a PE ratio of 58.13 and a beta of 0.05. The company has a 50 day moving average price of $12.12 and a 200 day moving average price of $10.44.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 10,000 shares of the stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $11.39, for a total transaction of $113,900.00. Following the completion of the transaction, the senior vice president directly owned 326,918 shares in the company, valued at approximately $3,723,596.02. This represents a 2.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On Theravance Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC boosted its stake in shares of Theravance Biopharma by 1,201.8% during the 1st quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 3,281 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock valued at $55,000 after acquiring an additional 781 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Theravance Biopharma in the 1st quarter valued at approximately $101,000. R Squared Ltd increased its holdings in shares of Theravance Biopharma by 636.6% in the 1st quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company's stock valued at $112,000 after acquiring an additional 10,822 shares during the last quarter. Finally, Creative Planning bought a new stake in shares of Theravance Biopharma in the 2nd quarter valued at approximately $139,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.